UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Smooth Skyride through a Rough Skyline: Bayesian Coalescent-Based Inference of Population Dynamics

Molecular biology and evolution, 2008-07, Vol.25 (7), p.1459-1471

2008

Link zum Volltext

Verfügbarkeit prüfen

Three roads diverged? Routes to phylogeographic inference

Trends in ecology & evolution (Amsterdam), 2010-11, Vol.25 (11), p.626-632

2010

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Clinical cancer research, 2022-11, Vol.28 (22), p.4843-4848

2022

Link zum Volltext

Verfügbarkeit prüfen

Inferring Species-Level Phylogenies and Taxonomic Distinctiveness Using Multilocus Data in Sistrurus Rattlesnakes

Systematic biology, 2011-07, Vol.60 (4), p.393-409

2011

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical cancer research, 2022-03, Vol.28 (6), p.1072-1086

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

Clinical cancer research, 2020-08, Vol.26 (16), p.4180-4185

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2024-05, Vol.30 (10), p.2011

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Clinical cancer research, 2023-12, Vol.29 (24), p.5008

2023

Link zum Volltext

Verfügbarkeit prüfen

Regulatory implications of ctDNA in immuno-oncology for solid tumors

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e005344

2023

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer

Clinical cancer research, 2021-04, Vol.27 (8), p.2126-2129

2021

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical cancer research, 2022-03, Vol.28 (6), p.1058-1071

2022

Link zum Volltext

Verfügbarkeit prüfen

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical cancer research, 2021-11, Vol.27 (21), p.5753-5756

2021

Link zum Volltext

Verfügbarkeit prüfen

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies

Clinical cancer research, 2020-12, Vol.26 (24), p.6406-6411

2020

Link zum Volltext

Verfügbarkeit prüfen

Unifying Vertical and Nonvertical Evolution: A Stochastic ARG-based Framework

Systematic biology, 2010-01, Vol.59 (1), p.27-41

2010

Link zum Volltext

Verfügbarkeit prüfen

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1225-1231

2018

Link zum Volltext

Verfügbarkeit prüfen

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

The lancet oncology, 2020-02, Vol.21 (2), p.250-260

2020

Link zum Volltext

Verfügbarkeit prüfen

US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3456-3457

2023

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

Clinical cancer research, 2020-03, Vol.26 (6), p.1208-1212

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

The oncologist (Dayton, Ohio), 2021-01, Vol.26 (1), p.e164-e172

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical cancer research, 2015-11, Vol.21 (21), p.4760-4766

2015

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Clinical cancer research, 2020-05, Vol.26 (10), p.2284-2289

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

Journal of clinical oncology, 2022-04, Vol.40 (11), p.1155-1162

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical cancer research, 2015-06, Vol.21 (12), p.2666-2670

2015

Link zum Volltext

Verfügbarkeit prüfen

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2108-2116

2023

Link zum Volltext

Verfügbarkeit prüfen

Noninvasive Diagnosis of Cellular and Antibody-Mediated Rejection by Perforin and Granzyme B in Renal Allografts

Human Immunology, 2006-10, Vol.67 (10), p.777-786

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(55)
Dissertationen
(1)

Sprache

Englisch
(56)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Oncology
(28)
Humans
(26)
United States
(19)
United States Food And Drug Administration
(17)
Female
(16)
Drug Approval
(11)
Adult
(10)
Male
(10)
Clinical Trials
(8)
Middle Aged
(8)
Aged
(7)
Aged, 80 And Over
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Breast Neoplasms - Drug Therapy
(6)
Metastasis
(6)
Treatment Outcome
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Smooth Skyride through a Rough Skyline: Bayesian Coalescent-Based Inference of Population Dynamics

Three roads diverged? Routes to phylogeographic inference

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Inferring Species-Level Phylogenies and Taxonomic Distinctiveness Using Multilocus Data in Sistrurus Rattlesnakes

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Regulatory implications of ctDNA in immuno-oncology for solid tumors

FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies

Unifying Vertical and Nonvertical Evolution: A Stochastic ARG-based Framework

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

Noninvasive Diagnosis of Cellular and Antibody-Mediated Rejection by Perforin and Granzyme B in Renal Allografts

Suchergebnisse filtern